广西师范大学“药用资源化学与药物分子工程国家重点实验室”专职科研岗人员，讲师。2020年毕业于广西师范大学并获得理学博士学位。主持国家自然科学基金-青年项目1项、广西自然科学基金-面上项目和青年项目各1项、国家重点实验室人才引进项目1项。迄今以第一作者身份/通讯作者身份在Journal of Medicinal Chemistry、European Journal of Medicinal Chemistry、Drug Delivery和Molecular Pharmaceutics等期刊发表SCI论文10余篇。
联系方式: zhangzl@mailbox.gxnu.edu.cn.
代表性论文：
1. Jiang M#, Li WJ#, Liang JZ#, Pang M#, Li SH, Xu G, Zhu MH, Liang H, Zhang ZL*, Yang F*. Developing a palladium(II) agent to overcome multi-drug resistance and metastasis of liver tumor by targeted multi-acting on tumor cell, inactivating cancer-associated fibroblast and activating immune response. Journal of Medicinal Chemistry, 2024, 67: Accepted.
2. Zhang ZL#, Zhang JZ#, Yang TF#, Li SH, Xu G, Liang H*, Yang F*. Developing an anticancer platinum(II) compound based on the uniqueness of human serum albumin. Journal of Medicinal Chemistry, 2023, 66: 5669–5684.
3. Yang TF#, Zhang ZL#, Zhang JZ#, Li YP, Li WJ, Liang H*, Yang F*. Developing a gallium(III) agent based on properties of the tumor micro-environment and lactoferrin: Achieving two-agent co-delivery and multi-targeted combination therapy of cancer. Journal of Medicinal Chemistry, 2023, 66: 793−803.
4. Xu SH, Luo WC, Zhu MH, Zhao L, Gao LJ, Liang H, Zhang ZL*, Yang F*. Human serum albumin-platinum(II) agent nanoparticles inhibit tumor growth through multi-modal action against tumor microenvironment. Molecular Pharmaceutics, 2024, 21: 346–357.
5. Wang XJ, Zhu MH, Li SH, Xu G, Zhang ZL*, Yang F*. Novel mono-, bi-, tri- and tetra-nuclear copper complexes that inhibit tumor growth through apoptosis and anti-angiogenesis. Journal of Inorganic Biochemistry, 2024, 250, 112403.
6. Zhang ZL, Yang TF, Zhang JZ, Li WJ, Li SH, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on human serum albumin nanoparticles: integrating bioimaging and therapy. Journal of Medicinal Chemistry, 2022, 65: 5392−5406.
7. Yang TF, Zhu MH, Jiang M, Yang F, Zhang ZL*. Current status of iridium-based complexes against lung cancer. Frontiers in Pharmacology, 2022, 13: 1025544.
8. Zhang JZ#, Zhang ZL#, Jiang M, Li SH, Yuan HL, Sun HB, Yang F*, Liang H*. Developing a novel gold(III) agent to treat glioma based onthe unique properties of apoferritin nanoparticles: inducing lethal autophagyand apoptosis. Journal of Medicinal Chemistry, 2020, 63: 13695−13708.
9. Zhang ZL, Zhang JZ, Jiang M, Zhao L, Li SH, Sun HB, Yang F*, Liang H*. Human serum albumin-based dual-agent delivery systems for combination therapy: acting against cancer cells and inhibiting neovascularization in the tumor microenvironment. Molecular Pharmaceutics, 2020, 17: 1405−1414.
10. Zhang ZL, Yu P, Gou Y, Zhang JZ, Li SH, Cai ML, Sun HB, Yang F*, Liang H*. Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate. Journal of Medicinal Chemistry, 2019, 62: 10630−10644.
11. Gou Y#, Zhang ZL#, Li DY, Zhao L, Cai ML, Sun ZW, Li YP, Zhang Y, Khan H, Sun HB, Wang T*, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model. Drug Delivery, 2018, 25: 321−329.
12. Wang J#, Gou Y#, Zhang ZL#, Yu P, Qi JX, Qin QP, Sun HB, Wu XY, Liang H*, Yang F*. Developing an anticancer copper(II) multitarget pro-drug based on the His146 residue in the IB subdomain of modified human serum albumin. Molecular Pharmaceutics, 2018, 15: 2180−2193.
13. Zhang Y#, Zhang ZL#, Gou Y, Jiang M, Khan H, Zhou ZP*, Liang H*, Yang F*. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin. Journal of Inorganic Biochemistry, 2017, 172: 1−8.
14. Zhang ZL, Gou Y, Wang J, Yang K, Qi JX, Zhou ZP, Liang SC*, Liang H*, Yang F*. Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 121: 399−409.
科研项目:
(1) 国家自然科学基金-青年项目（82404419），2025年1月至2027年12月（30万元，主持，在研）
(2) 广西自然科学基金-面上项目（2024GXNSFAA010129），2024年5月至2027年4月（10万元，主持，在研）
(3) 广西自然科学基金-青年项目（2022GXNSFBA035491），2022年4月至2025年3月（8万元，主持，在研）
(4) 省部共建药用资源化学与药物分子工程国家重点实验室人才引进课题（CMEMR2021-A01），2021年5月至2024年5月（50万元，主持，在研）